All In Biotech

Drug Trial Radar · NCT03165240

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy

Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Oct 5, 2017

Primary completion

Apr 16, 2020

Study completion May 7, 2020

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this current trial is to investigate the safety and tolerability of 3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting Enzyme inhibitor \[ACEi\] or Angiotensin-receptor blockers \[ARB\]. Secondary objective is to evaluate the change from baseline in Urine Albumin-to-Creatinine Ratio \[UACR\].

Conditions

  • Diabetic Nephropathies

Interventions

  • BI 690517Drug

    Film-coated tablet

  • EplerenoneDrug

    Film-coated tablet

  • PlaceboDrug

    Film-coated tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with drug related Adverse Events (AEs)Time frame: Up to 35 days

Locations

40 sites in 10 countries. Site status is shown where the registry gives one.

  • Steno Diabetes Center Copenhagen

    Gentofte Municipality, Denmark

  • Bispebjerg og Frederiksberg Hospital

    København NV, Denmark

  • Copenhagen University Hospital, Rigshospitalet

    København Ø, Denmark

  • Kolding Sygehus

    Kolding, Denmark

  • HOP d'Angers

    Angers, France

  • HOP Michallon

    La Tronche, France

  • HOP Bichat

    Paris, France

  • HOP la Milétrie

    Poitiers, France

  • HOP Nord Laënnec

    Saint-Herblain, France

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • InnoDiab Forschung GmbH

    Essen, Germany

  • Inamed GmbH

    Gauting, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Profil Institut für Stoffwechselforschung GmbH

    Neuss, Germany

  • Univ. Gen. Hosp. of Ioannina

    Ioannina, Greece

  • Iatriko of Athens Group/ Iatriko of P. Faliro

    P. Faliro, Greece

  • Iatriko Psychikou

    Psychikó, Greece

  • University General Hospital of Thessaloniki AHEPA

    Thessaloniki, Greece

  • Hospital Dr. Nélio Mendonça

    Funchal, Portugal

  • APDP - Associação Protectora dos Diabéticos de Portugal

    Lisbon, Portugal

  • CHULN, EPE - Hospital de Santa Maria

    Lisbon, Portugal

  • Hospital Beatriz Ângelo

    Loures, Portugal

  • Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António

    Porto, Portugal

  • Res.Inst.-Compl.Iss.Cardi.Dis.

    Kemerovo, Russia

  • City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow

    Moscow, Russia

  • Nonstate Private Healthcare Institution "Scientific Clinical Center of LLC Russian Railways"

    Moscow, Russia

  • Baltic Med,LLC Clinic BaltMed Ozerki

    Saint Petersburg, Russia

  • D & R s.r.o.

    Košice, Slovakia

  • Hospital A Coruña

    A Coruña, Spain

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital de Bellvitge

    L'Hospitalet de Llobregat, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Puerta de Hierro

    Majadahonda, Spain

  • Hospital Virgen Macarena

    Seville, Spain

  • Hospital Clínico de Valencia

    Valencia, Spain

  • CTC Sahlgrenska Universitetssjukhuset

    Gothenburg, Sweden

  • Sjukhuset, Härnösand

    Härnösand, Sweden

  • Universitetssjukhuset, Örebro

    Örebro, Sweden

  • CTC Clinical Trial Consultants AB

    Uppsala, Sweden

  • University Hospital of Wales

    Cardiff, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.